Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469384 | 0.90 | LARS1 (0.39) | RPS6KA1EPHX2ACACBACACAKDM4A | |
| SCHEMBL469558 | 0.90 | LARS1 (0.39) | RPS6KA1EPHX2ACACBACACAKDM4A | |
| SCHEMBL13035561 | 0.90 | RPS6KA1 (0.39) | RPS6KA1EPHX2DRD2ACACBACACA | |
| SCHEMBL13035591 | 0.90 | RPS6KA1 (0.39) | RPS6KA1EPHX2DRD2ACACBACACA | |
| SCHEMBL23939747 | 0.89 | RPS6KA1 (0.40) | RPS6KA1EPHX2DRD2BRD4KDM4A | |
| SCHEMBL3446339 | 0.87 | EPHX2 (0.38) | RPS6KA1EPHX2CA12CA1CA2 | |
| SCHEMBL12665665 | 0.87 | EPHX2 (0.38) | RPS6KA1EPHX2CA12CA1CA2 | |
| SCHEMBL13035541 | 0.87 | RPS6KA1 (0.38) | RPS6KA1EPHX2DRD2ACACBACACA | |
| SCHEMBL23939723 | 0.86 | RPS6KA1 (0.40) | RPS6KA1EPHX2DRD2ACACBACACA | |
| SCHEMBL19672999 | 0.86 | RPS6KA1 (0.40) | RPS6KA1EPHX2DRD2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2015-05-14 | — | — | US | disclosed |
| US-8895534-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8530452-B2 | Tricyclic boron compounds for antimicrobial therapy | MICURX PHARMACEUTICALS, INC. (KY) | 2013-09-10 | — | — | US | disclosed |
| US-8530452-B2 | Tricyclic boron compounds for antimicrobial therapy | MICURX PHARMACEUTICALS, INC. (KY) | 2013-09-10 | — | — | US | disclosed |
| WO-2013093615-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | US | disclosed |
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | MICURX PHARMACEUTICALS, INC. (KY) | 2013-06-27 | — | — | US | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7816344-B2 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165411-A1 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY | TBCA, TBCB, BTD | RPS6KA1 2137/4885EPHX2 4793/4885DRD2 4350/4885 |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | RPS6KA1 2442/4885EPHX2 4401/4885DRD2 4288/4885 |
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | RPS6KA1 2442/4885EPHX2 4401/4885DRD2 4288/4885 |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | OXA1L, TLR1, OXER1 | RPS6KA1 1308/4885EPHX2 1700/4885DRD2 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.